Literature DB >> 18628431

Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.

Dallas R English1, Joanne P Young, Julie A Simpson, Mark A Jenkins, Melissa C Southey, Michael D Walsh, Daniel D Buchanan, Melissa A Barker, Andrew M Haydon, Simon G Royce, Aedan Roberts, Susan Parry, John L Hopper, Jeremy J Jass, Graham G Giles.   

Abstract

Colorectal cancers arising from serrated polyps are characterized by the CpG island methylator phenotype (CIMP) and somatic mutation (V600E) in the BRAF proto-oncogene. Few epidemiologic studies have investigated risk factors for these tumors. We conducted a cohort study of 41,328 residents of Melbourne, Australia that included 9,939 participants of southern European origin and 31,389 of Anglo-Celtic origin. Colorectal adenocarcinomas were identified from population-based cancer registries. BRAF V600E mutation in tumors was determined using a PCR-based allelic discrimination method. Tumors were classified as CIMP positive when at least three of five markers (RUNX3, CACNA1G, SOCS1, NEUROG1, and IGF2) were methylated according to MethyLight analysis. Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated by Cox regression with adjustment for risk factors for colorectal cancer. During follow-up, 718 participants were diagnosed with colorectal cancer. CIMP assays were done for 579 and BRAF V600E mutation testing for 582. After adjustment for other risk factors, when compared with people of Anglo-Celtic origin, those of southern European origin had lower incidence of colorectal cancer that had CIMP (HR, 0.32; 95% CI, 0.16-0.67) or BRAF mutations (HR, 0.30; 95% CI, 0.16-0.58) but similar incidence of colorectal cancer without CIMP (HR, 0.86; 95% CI, 0.70-1.05) or BRAF (HR, 0.90; 95% CI, 0.74-1.11). People of southern European origin had lower risk of colorectal cancers with CIMP and BRAF mutation than people of Anglo-Celtic origin, which may in part be due to genetic factors that are less common in people of southern European origin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628431     DOI: 10.1158/1055-9965.EPI-08-0091

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  50 in total

1.  Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Authors:  Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from H&E-stained archival tissue sections.

Authors:  Teppei Morikawa; Kaori Shima; Aya Kuchiba; Mai Yamauchi; Noriko Tanaka; Yu Imamura; Xiaoyun Liao; Zhi Rong Qian; Mohan Brahmandam; Janina A Longtine; Neal I Lindeman; Charles S Fuchs; Shuji Ogino
Journal:  Am J Clin Pathol       Date:  2012-07       Impact factor: 2.493

Review 3.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

4.  Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.

Authors:  Noriko Tanaka; Curtis Huttenhower; Katsuhiko Nosho; Yoshifumi Baba; Kaori Shima; John Quackenbush; Kevin M Haigis; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

5.  Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.

Authors:  Jeong Mo Bae; Tae Hun Lee; Nam-Yun Cho; Tae-You Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

6.  Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology.

Authors:  Shuji Ogino; Meir Stampfer
Journal:  J Natl Cancer Inst       Date:  2010-03-05       Impact factor: 13.506

7.  The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.

Authors:  Shan Muhammad; Zheng Jiang; Zheng Liu; Kavanjit Kaur; Xishan Wang
Journal:  J Gastrointest Oncol       Date:  2013-03

8.  Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history.

Authors:  Daniel J Weisenberger; A Joan Levine; Tiffany I Long; Daniel D Buchanan; Rhiannon Walters; Mark Clendenning; Christophe Rosty; Amit D Joshi; Mariana C Stern; Loic LeMarchand; Noralane M Lindor; Darshana Daftary; Steven Gallinger; Teresa Selander; Bharati Bapat; Polly A Newcomb; Peter T Campbell; Graham Casey; Dennis J Ahnen; John A Baron; Robert W Haile; John L Hopper; Joanne P Young; Peter W Laird; Kimberly D Siegmund
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-01-13       Impact factor: 4.254

9.  Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas.

Authors:  Andrea N Burnett-Hartman; Polly A Newcomb; John D Potter; Michael N Passarelli; Amanda I Phipps; Michelle A Wurscher; William M Grady; Lee-Ching Zhu; Melissa P Upton; Karen W Makar
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

10.  Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Authors:  Shoko Kure; Katsuhiko Nosho; Yoshifumi Baba; Natsumi Irahara; Kaori Shima; Kimmie Ng; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-29       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.